Retrospective Study
Copyright ©The Author(s) 2018.
World J Gastrointest Endosc. May 16, 2018; 10(5): 83-92
Published online May 16, 2018. doi: 10.4253/wjge.v10.i5.83
Table 1 Characteristics of enrolled patients with gastric tumor
Parameter
Number132
Age (yr)71.0 ± 8.6
Gender (male/female)100/32 (75.8%/34.2%)
H. pylori status (positive/negative)68/64 (51.5%/48.5%)
Anti-coagulant administration (+/-)22/110 (16.7%/83.3%)
Acid suppressant post-ESD (lansoprazole/vonoprazan)97/35 (73.5%/26.5%)
CYP2C19 genotype (EM/IM/PM)40/51/22 (35.4%/45.1%/19.5%)
Endoscopic background of gastric mucosa
Atrophy (Kyoto A0+A1/Kyoto A2)20/112 (15.2%/84.8%)
Intestinal metaplasia (none + mild/severe)72/55 (56.7%/43.3%)
Diffuse redness (none/mild/severe)65/62 (51.2%/48.8%)
Tumor
Types (adenoma/cancer)16/116 (12.1%/87.9%)
Depth (mucosa/submucosa)118/14 (89.4%/10.6%)
Location of tumors (upper/middle/lower third)15/67/50 (11.4%/50.8%/37.8%)
ESD
Mean procedure time (min)76.4 ± 56.7
Mean resected ulcer area (mm2)671.9 ± 720.9
ESD-induced ulcer area
Reduction at 4 wk90.4% ± 10.7%
Mean ulcer area at 4 wk (mm2)71.3 ± 135.6
Reduction at 8 wk99.8% ± 0.6%
Mean ulcer area at 8 wk (mm2)2.8 ± 15.6